Estelle Marrer-Berger

Estelle Marrer-Berger

Company: 3T Biosciences

Job title: Chief Development Officer


Advancing Screening Methods for Both Targets & TCR Molecules to Boost Validation Strategy & Guarantee Patient Safety 9:05 am

Since TCR therapies have been known to cause off-target toxicities, it is vital for patient safety to ensure targets are localized and restricted to tumor cells, meanwhile TCRs are specific to antigen targets. Next-generation TCR and target screening methods and technologies can provide the optimal validation to prevent cross-reactivity and off-target effects to secure therapy…Read more

day: Pre-Conference Workshops

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.